Abstract:Sotalol, the most recently approved oral antiarrhythmic drug, has a unique pharmacologic profile. Its electrophysiology is explained by nonselective beta-blocking action as well as class III antiarrhythmic activity (including fast-activating cardiac membrane-delayed rectifier current blockade), which leads to increases in action potential duration and refractory period throughout the heart and in QT interval on the surface electrocardiogram. Its better hemodynamic tolerance than other beta-blockers may be a result of enhanced inotropy associated with class III activity. Sotalol's ability to suppress ventricular ectopy is similar to that of class I agents and better than that of standard beta-blockers. Unlike class I agents, its use in a postinfarction trial was not associated with increased mortality rate. Therapeutically, it has shown superior efficacy for prevention of recurrent ventricular tachycardia and ventricular fibrillation, which was the basis for its approval. In a randomized study, the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial, sotalol was associated with an increased in-hospital efficacy prediction rate (by Holter monitor or electrophysiologic study), reduced long-term arrhythmic recurrence rate with superior tolerance, and lower mortality rate than class I ("standard") antiarrhythmic drugs. Sotalol was 1 of 2 drugs selected for comparison with implantable defibrillators in the recent National Institutes of Health Antiarrhythmics versus Implantable Defibrillator (AVID) study. Sotalol appears to be a preferred drug for use with implantable defibrillators; unlike some other agents (eg, amiodarone) it does not elevate and, indeed, may lower defibrillation threshold. Although unapproved for this use, sotalol is active against atrial arrhythmias. It has shown efficacy equivalent to propafenone and quinidine in preventing atrial fibrillation recurrence, but it is better tolerated than quinidine and provides excellent rate control during recurrence. Sotalol's major side effects are related to beta-blockade and the risk of torsades de pointes (acceptably small if appropriate precautions are taken). Unlike several other antiarrhythmics (eg, amiodarone), it has no pharmacokinetic drug-drug interactions, is not metabolized, and is entirely renally excreted. Initial dose is 80 mg twice daily, with gradual titration to 240 to 360 mg/day as needed. The daily dose must be reduced in renal failure. On the basis of favorable clinical trials and practice experience, sotalol has shown a steadily growing impact on the treatment of arrhythmias during its 5 years of market availability, a trend that is likely to continue.

THE SYNTHESIS AND ANTIARRHYTHMIC ACTIVITY OF SOTALOL

Serum Metabolomics Analysis Reveals That Obvious Cardioprotective Effects of Low Dose Sini Decoction Against Isoproterenol-Induced Myocardial Injury in Rats

Electrophysiologic Study of the Effects of Esmolol Hydrochloride Produced by Our Country

The Synthetic Technology of Ranolazine

A simple and sensitive LC-MS/MS method for the determination of sotalol in rat plasma.

Synthesis of a Novel Antianginal Agent Ranolazine

[Design, Synthesis and Antiasthmatic Activities of NO-donating Seratrodast Derivatives].

Propranolol analogs containing natural monoterpene structures: synthesis and pharmacological properties

Comparing the Antiarrhythmia Action of the Extracts from Choerospondias Axillaris (roxb.) Burtt Et Hill

Sotalol: An important new antiarrhythmic

The antiarrhythmic activity of amino acid-containing derivatives of 1,4-naphthoquinone

Oral Bioavailability and Mass Balance Studies of a Novel Anti-arrhythmic Agent Sulcardine Sulfate in Sprague–Dawley Rats and Beagle Dogs

Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.

Synthesis and In Vivo Antiarrhythmic Activity Evaluation of Novel Scutellarein Analogues as Voltage-Gated Nav1.5 and Cav1.2 Channels Blockers

First Total Synthesis Of Antihypertensive Natural Products S-(+)-Xjp And R-(-)-Xjp

Comparisons of the electrophysiological effects of intravenous sotalol and propranolol on the immature mammalian heart

Effect of Amiodarone and Sotalol on Electrophysiological Characterist Ics in Rabbit Epicardium,midmyocardium,and Endocardium Across the Left Ventricu Lar Wall

Chemical Synthesis, Safety and Efficacy of Antihypertensive Candidate Drug 221s (2,9)

The Antiarrhythmic Activity of Novel Pyrrolidin-2-one Derivative S-75 in Adrenaline-Induced Arrhythmia

Synthesis and local anesthetic and circulatory actions of aminoesters and hydroxyamine monoterpene derivatives

Studies on the constituents of lateral root of Aconitum carmichaeli Debx. (Fu-Zi). I. Isolation and structural determination of salsolinol]